Lates News

Each SmartAI News, Great Wall Guorui Securities released a research report on June 18th, giving a buy rating to the First Medicine Holdings (688197.SH). The rating reasons mainly include: 1) focusing on the innovative small molecule drugs for NSCLC, and also having second-generation and third-generation ALK-TKIs; 2) the commercial value of the second-generation ALK-TKI is about to be released, and the clinical progress of the third-generation ALK-TKI is smooth; 3) the Chinese ALK-TKI market: the second-generation is dominant, and the differentiated competitive landscape is emerging; 4) SY-5007: a domestically produced selective RET-TKI with advanced research and development progress, in Phase III clinical follow-up. (Daily Economic News)